 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ABO1020 / Suzhou Abogen Biosci
Clinical, P3 data, Journal: Efficacy, immunogenicity, and safety of a monovalent mRNA vaccine, ABO1020, in adults: A randomized, double-blind, placebo-controlled, phase 3 trial. (Pubmed Central) - Oct 12, 2024
P2/3
ABO1020 was well tolerated and conferred 66.18% protection against symptomatic COVID-19 in adults.
- |||| ABO1020 / Suzhou Abogen Biosci
Trial primary completion date: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - Oct 10, 2023
P2/3, N=14168, Active, not recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
ABO1020 was well tolerated and conferred 66.18% protection against symptomatic COVID-19 in adults. Trial primary completion date: Jul 2023 --> Apr 2023
- ||||| ABO1020 / Suzhou Abogen Biosci
Enrollment closed: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - Apr 18, 2023
P2/3, N=15030, Active, not recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Trial primary completion date: Jul 2023 --> Apr 2023 Recruiting --> Active, not recruiting
- |||||| ABO1020 / Suzhou Abogen Biosci
Enrollment open, Phase classification, Enrollment change, Trial completion date, Trial primary completion date: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - Dec 20, 2022
P2/3, N=15030, Recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | Phase classification: P1/2 --> P2/3 | N=30 --> 15030 | Trial completion date: Nov 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Jul 2023
- | ABO1020 / Suzhou Abogen Biosci
Enrollment closed: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - Dec 7, 2022
P1/2, N=30, Active, not recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.
Active, not recruiting --> Recruiting | Phase classification: P1/2 --> P2/3 | N=30 --> 15030 | Trial completion date: Nov 2023 --> Jul 2024 | Trial primary completion date: Dec 2022 --> Jul 2023 Not yet recruiting --> Active, not recruiting
- |||||||||| ABO1020 / Suzhou Abogen Biosci
New P1/2 trial, New P2/3 trial: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS-CoV-2 Variant (BA.4 /5) mRNA Vaccine (clinicaltrials.gov) - Dec 5, 2022
P1/2, N=30, Not yet recruiting, Sponsor: Suzhou Abogen Biosciences Co., Ltd.